Persistent Link: https://ieeexplore.ieee.org/servlet/opac?punumber=11286140 ...

At 24 months, 86.4% of patients were disease-free in the ensartinib arm, compared to 53.5% of those in the placebo arm. Adjuvant ensartinib improves disease-free survival (DFS) compared to placebo ...

aDepartment of VIP Medical Services & Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and ...

PTNB before surgery in stage 1 NSCLC patients is linked to higher local-regional recurrence and mortality rates. The study included 2026 patients, with 38.6% undergoing PTNB, showing higher recurrence ...

Curative-intent multimodality treatment—combining local treatments such as surgery or radiotherapy with systemic therapy—is the cornerstone of care in stage II–III non-small cell lung cancer (NSCLC).

Sample management algorithm for average-risk patients. A. Resection suggested over stereotactic body radiotherapy or ablative techniques. B. Resection by a board-certified thoracic surgeon suggested.

The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients with early-stage non-small cell lung cancer (NSCLC). Published in the journal ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

Introduction Randomised controlled trials have aimed to assess the effectiveness of stereotactic ablative radiotherapy (SABR) with curative intent versus surgical resection for individuals diagnosed ...